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Summary 
Magnesium is an essential biological cation, participating in whole spectrum of biologi-
cal functions. It is an irreplaceable factor for more than 300 enzymatic reactions, including 
those that use ATP as chemical energy source. Only about 1% of whole body magnesium is 
present in plasma. Normal plasma concentrations are in a range: 0.75-1.00 mmol/L.
Concentrations lower or higher than in this interval are called hypomagnesemia and 
hypermagnesemia, respectively. Those are life treathening conditions. Hypomagnesemia 
requires quick i.v. supplementation with magnesium cation. In addition to hypoamgnese-
mia, we are nowadays aware of a common “invisible” deficit of magnesium in tissues. This 
is a result of changing nutrition habits causing an insufficient recommended daily uptake 
(>300mg daily). Large clinical studies have shown that magnesium status is negatively cor-
related with incidence and severity of diabetes type 2, metabolic syndrome, hypertension 
and some arrhythmias. Therefore, food supplementation with magnesium is one of positive 
therapeutic or prevention options. Future larger clinical studies are expected to provide 
information on usefulness of supplementation in some other common diseases and syn-
dromes (e.g. migraine, fibromyalgia, coronary artery disease, chronic fatigue syndrome).
Keywords: magnesium; hypomgnesemia; hypermagnesemia; therapeutic applications 
of magnesium.
INTRODUCTION
The fact that magnesium (Mg) is essential for life was for the first time described 
in animals by Leroy in 1926 [1]  and Kruse et al. in 1933 [2], while the first description 
of clinical depletion of Mg in humans was reported in 1934 by Hirschfelder & Haury 
[3]. However, studies of Mg began to gain increased attention only since 1950, after 
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descriptions of various pathological conditions related to Mg deficiency [4]. Such 
studies were additionally facilitated by advances in technology, i.e. the development 
of ever more sensitive and specific methods for determining Mg concentrations in 
different samples so that more and more information has become available on regu-
lation and biological functions of Mg at molecular level. 
SOURCES, RECOMMENDED ALLOWANCES AND MAGNESIUM 
DISTRIBUTION IN THE BODY
Intake of Mg in the body occurs via drinking water (approximately 30 mg/L in 
hard water) and food. Mg is abundant in green leafy vegatables (chlorophyll rich 
and containing Mg), seeds, leguminous plants, cereals, hazelnuts [5,6].  Fruit, ve-
getables, meat and fish contain small amounts of Mg, while this mineral is least 
present in dairy food [7].  Mg is reduced by as much as 85% in refined or processed 
food [8], which accounts for a high prevalence of low Mg intake in the body. 
It is well known that the entire quantity of ingested Mg is not absorbed in the 
body but only, on average, 30-50% [9]. To maintain serum Mg concentration within 
the reference interval (0.75-1.0 mmol/L) – which is the basis of Mg biological func-
tions, Recommended Dietary Allowance (RDA) values established in 1997 [10] for 
daily Mg intake are >300 mg (310-360 mg for women and 400-420 mg for men) and 
they have been adjusted for age, gender and nutritional status (Table 1). 
Table 1. Recommended dietary allowances (USA 1997) and reference intakes (Germany, 




1-3 80  80  
4-8 130  130  
9-13 240  240  
14-18 360 410 
19-30 310 400 
31-50 320 420 
51-70 320 420 
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Mg absorption occurs mostly in the small intestine, i.e. in the jejunum and ileum 
and significantly less in the colon [6]. Considering numerous factors that affect the 
process of absorption, the absorbed proportion of Mg is as stated above, commonly 
from 30% to 50% or 24-75% depending on body stores and food content [11]. The 
absorbed Mg is then distributed mostly to various tissue cells and to a lesser extent 
extracellularly. It is excreted through stool and through the kidneys. 
Regarding its presence in the body, Mg is the fourth most frequent cation 
(following calcium, sodium, and potassium) [12,13]. From average 25 g (or 1120 
mmol) of Mg in the body of an adult individual, the highest proportion of Mg can 
be found in bones, followed by muscles and other soft tissue cells [5,13]. One por-
tion (20-30%) of Mg in bones is replaceable and buffers acute changes in serum Mg 
concentration but this quantity is significantly reduced with years [14,15]. Extracel-
lularly, <1.0% Mg is found in three different forms: free ionized Mg, Mg complexed 
with different ligands, and as protein-bound Mg (Table 2). 
Table 2. Distribution and/or concentrations of magnesium in a healthy adult (modified 
according to ref. 10).












0.75-1.1 mmol/L (55% free; 13% complexes with 
citrate, phosphate, etc; 32% bound to proteins, 
primarily to albumin)
1.25 mmol/L (55% free, 45% complexed)
0.3 mmol/L (in warm environment)
PHYSIOLOGICAL FUNCTIONS OF MAGNESIUM
Magnesium is, after calcium, the second most frequent cation in cells [12]. 90% 
Mg in cells is bound to different ligands (e.g., nucleic acids, adenosine triphosphate, 
ATP, ADP, citrates, negatively charged phospholipids, proteins, etc.), while 10% Mg 
is in a free form. A significant amount of Mg is found in mitochondria (they are 
considered the major intracellular repository for Mg), then in the nucleus, riboso-
mes and endoplasmic reticulum  [10]. In cells, Mg has structural and dynamic roles 
as, for instance, stabilization of protein structure, of phosphate groups in lipids of 
cellular membranes, of negatively charged phosphates of nucleic acids, and acti-
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vation or inhibition of many enzymes [12,16,17]. Magnesium is actually important 
for the catalytic activity of more than 300 enzymes (e.g., ATP-ase, phosphofructoki-
nase, enolase, adenylate cyclase, creatine kinase, 5-phosphoribosyl pyrophosphate 
synthetase, DNA polymerase, etc.), particularly of those that catalyze energy me-
tabolism reactions. These reactions involve the process of glycolysis, Krebs cycle, 
respiratory chains, pentose phosphate pathway, gluconeogenesis, urea cycle, etc. In 
regulating enzyme activity, Mg can act as an allosteric modulator or as a co-factor, 
most frequently in the form of the Mg-ATP2- complex [13,18]. Generation of a com-
plex with ATP4- is important to facilitate transphosphorylation reactions which are 
decisive for cell activation/deactivation. The complex is also involved in regulating 
the activity of ion channels that are significant for the transport of other electrolytes, 
e.g. potassium and calcium [19]. 
The biological role of Mg is rather heterogeneous. In addition to the above-men-
tioned structural and dynamic function, Mg – due to its relatively small atomic ra-
dius – easily competes with other divalent cations (particularly calcium) for spe-
cific binding sites on proteins [18,20,]. As an endogenous calcium antagonist, Mg 
is involved in, e.g., blockage of N-methyl-D aspartate (NMDA) receptor, inhibition 
of excitatory neurotransmitter release, blockage of Ca channels, and relaxation of 
vascular smooth muscle cells [21]. This characteristic, and that of binding to various 
ligands – particularly to ATP4-, – is the basis for different physiological functions 
of Mg. Among other uses, Mg is essentially necessary for maintenance of normal 
neurological function and neurotransmitter release [6,8,13,22,23], muscular contrac-
tions/relaxations [6,9,24,25], regulation of vascular tonus and blood pressure [26,27, 
28], of cardiac rhythm, [29,30,31], insulin signal transmission [32,33,34], parathormo-
ne secretion and activity [13,19,35], modulation of immunological functions [36,37], 
etc. It is therefore evident that tight regulation of Mg levels in blood /serum and Mg 
distribution to individual cell types are of vital importance. 
MAGNESIUM HOMEOSTASIS
Although the importance of Mg in different physiological and biochemical pro-
cesses is well known, direct hormonal control of Mg homeostasis has not been cle-
arly described [38,39]. This is accounted for by Mg abundance in food during human 
evolution [10]. Indirect activity of hormones is mostly described at the level of inte-
stinal absorption or renal tubular reabsorption. It is, actually, not known if hormone 
concentrations are under the influence of Mg status, which is the case when real 
hormonal control is present. The hormones in question are, e.g., calciotropic hor-
mones (parathyreoid hormone, PTH, calcitonin and vitamin D) and, more rarely, 
insulin, glucagon, prostaglandins, epinephrine, aldosteron, etc. [40,41,42,43,44]. Mg 
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is, for instance, critical for maintenance of calcium homeostasis as it regulates PTH 
production and secretion, maintains adequate sensitivity of target tissues to PTH, 
is a cofactor of 1-alpha hydroxylase, an enzyme that participates in 1,25(OH)2 D3 
production, and also many calcium channels are dependent on Mg [45]. Besides its 
effect on calcium levels, Mg helps in regulation of other electrolytes (copper, zinc, 
potassium, sodium, etc.) so that the understanding of Mg homeostasis is important 
not only to understand disturbances in Mg levels but also for understanding and 
treatment of abnormalities of other electrolytes. 
Magnesium homeostasis is controlled by dynamic interrelationships between 
intestinal absorption and by exchange with bones, but mostly by renal excretion 
[6,39,46]. 
Magnesium absorption
Mg absorption in the small intestine occurs primarily via non-saturable (passi-
ve) paracellular, and to a lesser extent by saturable (active) transcellular mechanisms 
[6,9,46,47,48]. 
The paracellular, passive mechanism involves absorption through small perme-
able spaces between epithelial cells (tight junction), and is responsible for 80-90% 
of Mg uptake in the body. This transport mechanism also includes some proteins 
from the claudin family (e.g., pracellin-1 or claudin-16) whose role is still at research 
stage [9,49]. Transcellular active transport to blood through the interior of intestinal 
epithelial cells is subject to tight regulation because ions must pass through apical 
and basolateral membrane. This mechanism includes specific channels (transient 
receptor potential channel melastatin - 6 and 7; TRPM-6 and 7) that are expressed 
on apical/luminal membrane of enterocytes [9,49,50,51]. It seems that the transport 
on basolateral membranes is associated with sodium gradient and corresponding 
activity of Na+, K+-ATPase [9]. 
Magnesium absorption in the intestines is generally dependent on the factors 
like the following: fiber rich food – phytates, organic acids, pH, Mg quantity, intesti-
nal passage, meal volume and viscosity, vitamin D, calcium, phosphorus, polyphe-
nols, oxalates, zinc, etc. [52,53,54,55,56].
Magnesium excretion  
As serum Mg concentration is primarily controlled through urinary excretion, 
kidneys are considered the major regulators of Mg homeostasis. They have the abi-
lity to reduce Mg excretion to 0.5% of the filtered quantity in case of decreased se-
rum concentrations, and to increase Mg excretion to 80% in case of elevated serum 
Mg concentrations [57,58]. 
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Magnesium is filtered in glomerules (approximately 2400 mg/day), 90-95% of the 
filtered quantity is immediately reabsorbed, and only 3-5% is excreted, i.e. 100 mg/
day [9,48]. To a lesser extent, reabsorption occurs via passive transport in proximal 
tubules (10-25%) [9], a significant proportion of 50-70% is reabsorbed in the thick as-
cending limb of the Henle’s loop, and about 10% is reabsorbed in the distal part [6, 9, 
59]. Magnesium reabsorption in the thick ascending limb of the Henle’s loop occurs 
via passive paracellular pathway because of the electrochemical gradient that re-
sults in potassium exit through channels (renal outer medulla potassium channel, 
ROMK) in the apical cell membrane of the above-mentioned segment of the Henle’s 
loop [60]. Reabsorption is at this stage further facilitated by claudin-16 (paracellin-1) 
and claudin-19 [50,61,62]. 
Ca2+/Mg2+- sensing receptor, CASR, that activates or inhibits Na+-K+-2Cl- co-tran-
sporter and  ROMK channel on the apical side in conditions of hypomagnesemia or 
hypermagnesemia [63,64], is located on the basolateral cell membrane of the thick 
ascending limb of the Henle’s loop and of the distal tubules.  
Reabsorption in distal tubules is utilized to determine the final quantity of Mg 
that is to be excreted by urine. Reabsorption occurs via transcellular active mecha-
nism that involves Mg entry into cells through the TRPM6 channel on the apical 
membrane (the role of TRPM7 channel is still investigated).  It has been assumed 
that Mg exit from the cell on the basolateral membrane is facilitated, against con-
centration gradient, by the Na+/Mg2+- dependent mechanism of exchange and/or Mg-
ATPaze activity [64,65]. 
The processes of absorption and reabsorption are controlled by different regu-
latory factors. Thus, for instance, Mg intake through food and changes in TRPM6 
expression play a role in regulating intestinal absorption [9]. Stimulation of absor-
ption in the intestines with 1,25-dihydroxy vitamin D3 ((1,25(OH)2D3) was also des-
cribed [66]. A regulatory factor of Mg reabsorption in kidneys is, e.g., epidermal 
growth factor (EGF) which regulates the activity of TRPM6 [67] whose expression is 
stimulated by estrogens [68].
Examination of Mg homeostasis at the level of cells themselves, i.e. Mg entry and 
exit from cells and its transport between cellular organelles via various pathways, 
carriers and exchangers, is in the focus of numerous studies that are currently un-
derway. A reader is referred to an excellent review article by A.M Romani [12]. 
DISORDERS OF SERUM MAGNESIUM CONCENTRATIONS
 Changes in serum Mg concentrations, related to reduced or increased levels 
outside the lower or upper limit of the reference interval (0.7-1.0 mmol/L), are termed 
hypomagnesemia and hypermagnesemia, respectively.
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The occurrence of hypomagnesemia is more frequent, with the prevalence of 
6.9% in general population and 7-11% among hospitalized patients [5, 69]. Hypoma-
gnesemia in intensive care units ranges from 20% to 65% [70] and very frequently 
remains undetected. Some reports indicate a correlation between severe hypoma-
gnesemia and increased mortality [71] so that it is recommended to monitor Mg 
concentration in severe patients.  
Data on the prevalence of hypermagnesemia differ considerably and vary from 
5.7% to 9.3% [13, 72]. Clinical findings related to serum Mg concentrations outside 
the reference interval are presented in Table 3. 
Table 3. Clinical reports associated with altered magnesium concentrations (ref. 39).
Total  Mg (mmol/L) Report
<0.5 Tetany, convulsions, arrhythmias
0.5-0.7 Neuromuscular irritability 
0.7-1.0 Reference interval 
1.0-2.1 Typically without symptoms   
2.1-2.9 Lethargy/listlessness, sleepiness, redness, nausea and vomiting, weakened reflexes of deep tendons 
2.9-5.0 Drowsiness, weakened reflexes of deep tendons, hypotension, ECG changes 
>5.0 Complete heart blockage, cardiac arrest, apnea, paralysis, coma  
Symptoms of acute hypo- and hypermagnesemia partially overlap so that se-
rum Mg concentration must be determined [6]. 
a) Hypomagnesemia 
Hypomagnesemia and Mg deficiency in the body are the terms that are equ-
ally often used in practice, mostly referring to decreased serum Mg concentration. 
However, depletion of the total body Mg may be present with serum Mg concen-
trations being within the reference interval while, on the other hand, significant 
hypomagnesemia is possible without body Mg deficiency. In fact, the determination 
of the total serum Mg concentration is not the best method to evaluate Mg status in 
the body as there is very weak correlation between the levels of total serum Mg and 
total Mg status in the body.    
Hypomagnesemia may be the consequence of decreased Mg intake, of Mg re-
distribution, and the consequence of extrarenal, renal and hereditary factors. Etiolo-
gical factors of hypomagnesemia are summarily presented in Table 4.
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Table 4. Etiology of hypomagnesemia (modified according to ref. 64)
Reduced Mg intake through food 
Increased Mg loss via gastrointestinal tract: diarrhea, malabsorption, steathorrhea, small 
bowel bypass
Increased Mg excretion by kidneys: extracellular volume expansion, hypercalcemia, re-
nal diseases, drugs (e.g. diuretics - thiazides, furosemide; amino glycoside antibiotics; 
cyclosporine; cisplatin inhibitors of proton pump, beta-adrenergic agonists, immunosup-
pressants, amphotericin B, foscarnet, etc.) 
Hereditary causes:
-  Intestinal and renal: hypomagnesemia with secondary hypocalcemia (TRPM-6 mutati-
ons)
-  Renal: Bartter syndrome, Gitelman syndrome, familial hypomagnesemia with hypercal-
ciuria and nephrocalcinose; autosomal dominant hypomagnesemia with hypocalciuria; 
isolated recessive hypomagnesemia, autosomal dominant hypocalcemia
Other etiologies: acute pancreatitis, alcohol induced tubular dysfunction, hungry bones 
syndrome, diabetes mellitus, enhanced sweating, increased requirements (pregnancy, 
growth) 
Individuals with hypomagnesemia are often asymptomatic as Mg deficiency is 
usually secondary to other disease processes or drugs so that primary disease dis-
guises Mg deficiency.
The signs and symptoms of hypomagnesemia depend more on the rapidity of 
decline in Mg levels than on serum Mg concentration itself [13], and they are usually 
not observed until serum Mg level drops below 0.5 mmol/L or lower. Clinical and 
biochemical manifestations of hypomagnesemia include the most frequent disor-
ders of other electrolytes, disorders of cardiovascular, neuromuscular and central 
nervous system, complications due to Mg deficiency like hypertension, osteoporo-
sis, glucose homeostasis disorder, atherosclerotic vascular disease and, e.g., migra-
ine, asthma, etc.
Development of hypocalcemia in hypomagnesemia is associated with the role 
of Mg in the synthesis, secretion, and activity of parathormones on target tissues, 
and with the activity of  1,25(OH)2D3. [73]. A significant proportion of individuals 
(40-60%) with hypomagnesemia also have hypopotassemia [72], and the mechani-
sm involves the following: a) concurrent loss of Mg and potassium due to diarrhea 
or application of diuretics, and b) decline in the activity of Na+, K+-ATPase, that is, 
increase in the number of open potassium channels in the cells of the thick limb 
of the Henle’s loop and collecting tubules [74, 75]. The hypopotassemia associated 
with hypomagnesemia is often refractory to potassium treatment so that Mg de-
ficiency should also be corrected. Due to impaired electrical activity, myocardial 
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contractility and vascular tonus, cardiovascular disorders include, for instance, 
hypertension, dysrhythmias, ECG changes (e.g., prolonged QT interval, prolonged 
PR interval), atherogenic dyslipidemia, oxidative stress, impaired coagulation pro-
cess, aggravated inflammatory problems, etc. [76,77,78].
Neuromuscular disorders, or neuromuscular hyperexcitability, are frequent in 
individuals with hypomagnesemia and involve, e.g., tetany, spontaneous carpal-
pedal spasm, vertigo, ataxia, muscular weakness, convulsions, nystagmus, and 
psychiatric disorders like depression and psychosis, etc. [77,79]. The mechanism of 
the development of neuromuscular disorders is related to decreased axon stimula-
tion threshold and increase in nerve conduction velocity due to reduced Mg con-
centration. Besides, as Mg participates in neurotransmitter (glutamate) release at 
neuromuscular junctions [80] and thus inhibits the calcium entry into presynaptic 
nerve terminals, enhanced calcium entry occurs in the situation of Mg deficiency 
and consequently of increased neurotransmitter release, which results in enhanced 
neuromuscular activity. Hypocalcemia is often concurrent with hypomagnesemia 
and it further contributes to neurological signs.    
In case of inherited types of hypomagnesemia, whose molecular mechanisms 
have been discovered during the past ten years, they involve gene mutations for 
different proteins - channels, carriers, transporters [9,48,49], some of which are pre-
sented in Table 5. 
Table 5. Some proteins of molecular magnesium homeostasis are related to hereditary 
hypomagnesemia.













NCCT SLC12A3 (Na+ Cl— cotransporter) Gitelman syndrome
TRPM-6 TRPM6 Selective Mg channel Hypomagnesemia withsecondary hypocalcemia
Na+, K+ -ATPase 
gamma subunit FXYD2
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Hypomagnesemia therapy includes oral Mg replacement in food or food supple-
ments in mild cases [39, 81] while intravenous replacement is applied in severe hypo-
magnesemia, most frequently in the form of Mg- sulfate [8, 82]. 
b) Hypermagnesemia 
Hypermagnesemia is a condition where serum Mg concentration is >1.0 mmol/L. 
Mild hypermagnesemia is quite common in hospitalized patients and is usually not 
associated with clinical symptoms. Significant hypermagnesemia is related to diffe-
rent neuromuscular and cardiovascular disorders, and very severe hypermagnese-
mia may result in a coma.  
One of the causes of hypermagnesemia is increased oral, rectal or parenteral 
intake of high Mg doses as, e.g., Mg supplementation in the form of magnesium 
salts or Mg-containing drugs (antacides, laxatives, purgatives), in some therapeutic 
approaches involving intravenous Mg application (e.g., torsade de pointes therapy 
of specific types of arrhythmia or convulsions in patients with eclampsia). Another 
cause is renal function impairment (acute and chronic diseases, rhabdomyolysis) 
because kidneys are the main organ that maintains Mg homeostasis (normal Mg 
concentration is maintained until glomerular filtration rate drops below 30 mL/min 
[13]. In such cases, renal compensatory mechanisms to maintain Mg homeostasis 
become inadequate and hypermagnesemia develops. Other causes include Mg re-
distribution to cells and, e.g., lithium therapy, familial hypocalciuric hypercalcemia, 
theophylline toxicity, etc. [39,83,84].   
Signs and symptoms of hypermagnesemia occur at different Mg concentrations 
but they usually occur when serum concentrations are >2.0 mmol/L [13]. However, 
cases with very high serum Mg concentrations, i.e. 13.0 mmol/L [85], 17.0 mmol/L 
[86], 21.5 and 22. 5 mmol/L, have been described in the literature [87]. 
Clinical manifestations of hypermagnesemia include the most frequent neuro-
muscular and cardiovascular disorders (Mg is cardiotoxic in serum concentrations 
>3 mmol/L), nausea, and vomiting (Table 6). 
Table 6. Clinical manifestations of hypermagnesemia (reprinted from ref.13)
Neuromuscular manifestations: confusion, lethargy, respiratory depression, absent 
tendon reflexes, paralytic ileus, bladder paralysis, muscle weakness/paralysis
Cardiovascular manifestations: hypotension, bradycardia, inhibition of AV and 
intraventricular conduction, heart block, cardiac arrest
Others: nausea, vomiting
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With regard to biochemistry disorders, hyperpotassemia and hypocalcemia 
also occur in addition to hypermagnesemia [13,39]. 
Hypermagnesemia therapy involves discontinued Mg application and Ca-
gluconate administration, while severe types of hypermagnesemia may even requ-
ire hemodialysis [7]. 
CLINICAL ASPECTS 
Physiological function of Mg in the body are numerous and varied (modulati-
on of transport functions, of enzymatic activities, energy metabolism, synthesis of 
proteins and nucleic acids, etc.). It is, therefore, not surprising that Mg deficiency is 
involved in pathogenesis of a large number of pathological conditions (Table 7), with 
concurrent accumulation of data on the benefits of supplementing Mg as a pharma-
cological compound.  
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Early recognition of disorders of Mg metabolism (and its consideration with 
changes in other electrolytes) and their correction are necessary to avoid compli-
cations related to cardiac arrhythmia, hypocalcemia, etc. It is therefore necessary 
to frequently determine Mg in serum and possibly start Mg supplementation. Cu-
rrently, different methodological approaches are available to estimate Mg status: 
methods for determination of total serum Mg concentration [6, 13, 77, 157], of ioni-
zed Mg form in whole blood, serum or plasma [13,48, 158], methods for Mg determi-
nation in erythrocytes [159], leukocytes [160], and skeletal muscle cells [25, 77, 161]. 
Magnesium may also be measured in urine, saliva, hair, and teeth [6,159]. In some 
clinical conditions, physiological tests are used as, e.g., Mg balance test, Mg excreti-
on in 24-h urine, Mg loading test, Mg tolerance test [13, 162]. Recently, dry chemistry 
methods have also been developed for determination of ionized Mg for point-of-ca-
re testing [163]. Furthermore, for determination of ionized Mg concentration in the 
cell cytosol, the procedures with different metalochromatic or fluorescent dyes are 
used, as well as Mg-selective electrodes, and nuclear magnetic resonance and isoto-
pe testing [13, 48] which are mostly limited to scientific investigations. 
Regarding therapy, Mg is usually administered in case of constipation [164] and 
dyspepsia [82]. According to reports by Guerera MP, et al. [82] and Geiger H, et 
al. [98] from 2012, indications for therapeutic applications of Mg (it has shown to 
be highly effective when applied intravenously) are primary reduction of the risk 
for eclampsia in preeclamptic women,  arrhythmias (torsade de pointes in patients 
with long QT syndrome and digoxin induced arrhythmia), and severe asthma and 
migraine attacks. 
Favorable effects of Mg have been observed in the control of glycemia in type 2 
diabetes, improved efficacy of antihypertensive therapy, reduction in the frequency 
of muscular cramps, favorable effects on some risk factors of atherosclerosis, pre-
vention of osteoporosis, of renal stone recurrence, of stroke, etc.
Although oral Mg supplementation is generally well tolerated, the following si-
de-effects have been observed: nausea, vomiting, diarrhea, whereas large amounts 
of magnesium may result in hypotension, muscular weakness and coma. Mg must 
not be administered as therapy to patients with any type of renal dysfunction. 
CONCLUSION 
It is well known that Mg is the essential element for human health. However, 
due to increasing intake of Mg-deficient processed food, Mg deficiency may be 
expected to develop into a significant public health problem. It is not uncommon 
that hypomagnesemia is already a relatively frequent disorder which is, moreover, 
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often not recognized/not diagnosed because Mg concentration is seldom routinely 
determined. Actually, the evaluation of the Mg status is made difficult by the fact 
that most Mg is stored in tissues so that serum Mg levels are not representative. 
Generally accepted attitude is, however, that physicians should request Mg concen-
tration measurement regardless of this difficulty, particularly in patients with the 
risk of possible hypomagnesemia.    
As the low Mg intake may result in various, even severe, diseases, or contribute 
to complications that accompany different illnesses, it is necessary that researchers 
have thorough knowledge of those conditions in order to be able to assess symp-
toms related to Mg deficiency. In this regard, the application of novel analytical 
procedures in determining total and ionized Mg in different body fluids and cells, 
numerous clinical observations, and molecular genetic studies will certainly contri-
bute to elucidation of the Mg role in terms of physiology and pathophysiology and 
particularly with regard to Mg deficiency treatment.  
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Sažetak
Magnezij – više od običnog kationa
Magnezij je kation koji je vrlo bitan, nezamjenjiv, za brojne aspekte biologije stanice. Ta 
se tvrdnja najbolje zrcali u činjenici da je nezamjenjivi kofaktor za više od 300 enzimskih 
reakcija, uključujući najveći broj onih koje upotrebljavaju ATP kao izvor energije. Samo oko 
1% ukupnog magnezija u organizmu čovjeka nalazi se u plazmi. Normalne koncentracije 
kreću se od 0.75 do 1.00 mmol/L. 
Smanjena, odnosno povećana, koncentracija magnezija u plazmi naziva se hipoma-
gnezijemija, odnosno hipermagnezijemija. Hipomagnezijemija može biti za život opasno 
stanje koje treba brzo sanirati povećanim (i.v.) unosom magnezija. Danas je poznato da, 
uz kliničku hipomagnezijemiju, vrlo često postoji i „nevidljiv“ deficit magnezija u tkivima. 
Najčešće se javlja kao posljedica moderne prehrane, koja često ne zadovoljava dnevne 
preporučene doze (> 300mg dnevno). Kliničke studije pokazuju da su bolesti poput meta-
boličkog sindroma, dijabetesa tipa 2, nekih aritmija te hipertenzije, u pogledu pojavnosti i 
težine obolijevanja, u obrnutoj korelaciji s magnezijskim statusom organizma. Stoga je do-
davanje magnezija prehrani jedna od mogućnosti pozitivnog utjecaja na spomenute bolesti. 
Od budućih kliničkih studija očekuje se jasna procjena opravdanosti magnezija kao dodatka 
prehrani i u nekim drugim bolestima i sindromima (migrena, fibromijalgija, bolest koronar-
nih arterija, kronični sindrom umora).
Ključne riječi: magnezij; hipomagnezijemija; hipermagnezijemija; terapijske aplikacije 
magnezija.
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